Medical Updates

Dolutegravir-based Regimen Noninferior to EFV400-based in HIV-1–infected Adults in Cameroon

An efavirenz-based regimen (with a 600-mg dose of efavirenz, known as EFV600) was preferred first-line treatment for human immunodeficiency virus...

13 Aug, 2019

 
Email this page
Neural-tube Defects with Exposure to ART at Conception

Dolutegravir is a newer antiretroviral agent with a higher barrier to resistance, fewer side effects, and more effective viral suppression than...

07 Aug, 2019

 
Email this page
Factors Influencing HIV RNA Concentration in CSF During ART

CNS HIV AntiRetroviral Therapy Effects Research (CHARTER) is a six-site, prospective, observational study that was designed to comprehensively...

30 Jul, 2019

 
Email this page
Once Daily Low dose of Darunavir/Ritonavir Non-inferior to Lopinavir/Ritonavir in Patients with HIV RNA Suppression

In low-income and middle-income countries (LMICs), ritonavir-boosted lopinavir is the most commonly used second-line protease inhibitor. However, it...

25 Jul, 2019

 
Email this page

Key Trials

TAF Based Regimen Superior to TDF–based Regimen in Efficacy and Renal and Bone Safety for Initial HIV-1 Treatment

This was a 144-week analysis comparing the efficacy and safety of TAF vs TDF, each co-formulated with elvitegravir, cobicistat, and emtricitabine (e...

Safety and Efficacy of E/C/F/TAF vs E/C/F/TDF in Treatment Naïve HIV Patients

This trial compares the safety and efficacy of TAF vs TDF co-formulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of...

REALITY: Enhanced Antimicrobial Prophylaxis + ART Improves Survival in Advanced HIV Patients

This study compared the enhanced and standard antimicrobial prophylaxis treatment in patients with advanced HIV disease.

Pre-exposure Chemoprophylaxis with Oral FTC–TDF Prevents HIV Acquisition in Men Who have Sex with Men

Pre-exposure Prophylaxis Initiative (iPrEx) trial was a randomized, double-blind, placebo controlled trial aimed to evaluate the safety and efficacy...

Our Publications

Antiretroviral-based Prevention Strategies in HIV

Today, antiretroviral therapy (ART) is not only known to keep HIV-infected patients alive but is also being harnessed as a strategy to prevent...

Antiretroviral Therapy – Current Recommendations

Advances in the treatment of HIV infection has resulted in a dramatic shift, from a deadly infectious disease to a chronic manageable condition....

Datasheet: Lopinavir and Ritonavir (40mg/10mg) Oral Pellets

Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This datasheet contains the entire...

Fast Facts: Lopinavir and Ritonavir (40 mg/10 mg) Oral Pellets

Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This booklet contains information about...

Patient Education

Live Healthier, Live Longer

This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment....

Living with Hope

This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects. ...

Slide Library

HIV - HCV Coinfection

This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...

 
Email this page
HIV - Pre-exposure Prophylaxis (PrEP): Guidance on PrEP Use

PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...

 
Email this page
HIV- Post-exposure Prophylaxis (PEP)

Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...

 
Email this page
Isoniazid Preventive Therapy in HIV Infection

HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....

 
Email this page

Poll

Which is your preferred 3rd drug in a first-line regimen?
Efavirenz 600
60% (3 votes)
Efavirenz 400
0% (0 votes)
Dolutegravir
40% (2 votes)
Total votes: 5